Standard BioTools (LAB) Stock Price
Standard BioTools Price
Revenue has compounded at 14.6% per year over the past 19 years to 85.33 M USD. Standard BioTools's net margin stands at -87.8%, down from -45.4% several years earlier. Analysts set a median price target of 1.58 USD, implying 105.4% above the current price. Of 7 analysts, 4 rate the stock a buy — an overall Buy consensus. The stock trades about 19% above its 52-week low.
Standard BioTools stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Standard BioTools over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Standard BioTools stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Standard BioTools's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Standard BioTools Price |
|---|---|
| 9/18/2026 | 0.77 USD |
| 9/17/2026 | 0.73 USD |
| 9/16/2026 | 0.72 USD |
| 9/15/2026 | 0.70 USD |
| 9/14/2026 | 0.70 USD |
| 9/13/2026 | 0.69 USD |
| 9/11/2026 | 0.69 USD |
| 9/10/2026 | 0.69 USD |
| 9/9/2026 | 0.73 USD |
| 9/8/2026 | 0.67 USD |
| 9/4/2026 | 0.69 USD |
| 9/3/2026 | 0.67 USD |
| 9/2/2026 | 0.67 USD |
| 9/1/2026 | 0.65 USD |
| 8/31/2026 | 0.66 USD |
| 8/30/2026 | 0.65 USD |
| 8/28/2026 | 0.65 USD |
| 8/27/2026 | 0.65 USD |
| 8/26/2026 | 0.65 USD |
| 8/25/2026 | 0.65 USD |
| 8/24/2026 | 0.66 USD |
| 8/21/2026 | 0.67 USD |
| 8/20/2026 | 0.65 USD |
| 8/19/2026 | 0.69 USD |
| 8/18/2026 | 0.68 USD |
| 8/14/2026 | 0.71 USD |
| 8/13/2026 | 0.75 USD |
| 8/12/2026 | 0.79 USD |
| 8/11/2026 | 0.79 USD |
| 8/10/2026 | 0.79 USD |
Standard BioTools Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Standard BioTools Income Statement, Balance Sheet, Cash Flow Statement
| REVENUEM USD |
|---|
| REVENUE GROWTH% |
| GROSS MARGIN% |
| GROSS INCOMEM USD |
| EBITM USD |
| EBIT MARGIN% |
| NET INCOMEM USD |
| NET INCOME GROWTH% |
| SHARESM |
| 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | 2027e | 2028e | 2029e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 116.00 | 114.00 | 104.00 | 101.00 | 112.00 | 117.00 | 138.00 | 130.00 | 97.00 | 106.00 | 174.00 | 85.00 | 82.00 | 82.00 | 85.00 | 89.00 |
| 63.38 | -1.72 | -8.77 | -2.88 | 10.89 | 4.46 | 17.95 | -5.80 | -25.38 | 9.28 | 64.15 | -51.15 | -3.53 | – | 3.66 | 4.71 |
| 62.93 | 59.65 | 55.77 | 50.50 | 54.46 | 54.70 | 60.14 | 59.23 | 38.14 | 47.17 | 48.28 | 49.41 | 49.41 | 49.41 | 49.41 | 49.41 |
| 73.00 | 68.00 | 58.00 | 51.00 | 61.00 | 64.00 | 83.00 | 77.00 | 37.00 | 50.00 | 84.00 | 42.00 | 40.52 | 40.52 | 42.00 | 43.98 |
| -51.00 | -50.00 | -73.00 | -58.00 | -47.00 | -62.00 | -50.00 | -67.00 | -188.00 | -76.00 | -175.00 | -93.00 | -35.00 | -58.00 | -50.00 | -54.00 |
| -43.97 | -43.86 | -70.19 | -57.43 | -41.96 | -52.99 | -36.23 | -51.54 | -193.81 | -71.70 | -100.57 | -109.41 | -42.68 | -70.73 | -58.82 | -60.67 |
| -52.00 | -53.00 | -75.00 | -60.00 | -59.00 | -64.00 | -53.00 | -59.00 | -190.00 | -74.00 | -138.00 | -74.00 | -38.00 | -61.00 | -53.00 | -57.00 |
| 246.67 | 1.92 | 41.51 | -20.00 | -1.67 | 8.47 | -17.19 | 11.32 | 222.03 | -61.05 | 86.49 | -46.38 | -48.65 | 60.53 | -13.11 | 7.55 |
| 28.23 | 28.81 | 29.15 | 38.70 | 41.49 | 69.71 | 74.28 | 76.65 | 79.43 | 79.73 | 374.54 | 385.05 | 385.05 | 385.05 | 385.05 | 385.05 |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Standard BioTools generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Standard BioTools retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Standard BioTools's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Standard BioTools has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Standard BioTools's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Standard BioTools stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Standard BioTools Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Standard BioTools business model & stock analysis
Standard BioTools SWOT Analysis
Strengths
1. Innovative Products: Fluidigm Corp is known for its advanced and cutting-edge technologies that enable the analysis of individual cells, empowering researchers with high-throughput and single-cell analysis capabilities.
2. Strong Intellectual Property (IP) Portfolio: The company possesses a significant number of patents and intellectual property rights, providing a competitive advantage and protection against potential imitators in the market.
3. Market Leadership: Fluidigm Corp holds a prominent position in the life sciences industry, with a strong brand reputation and a wide customer base that includes leading academic institutions, biotechnology companies, and pharmaceutical organizations.
Weaknesses
1. Reliance on Research Funding: The company heavily depends on government grants and research funding, which can be unpredictable and subject to budget constraints, potentially impacting their financial stability.
2. High Research and Development (R&D) Costs: Developing and commercializing highly innovative products require substantial investments in R&D, which puts pressure on the company's financial resources and profitability.
3. Market Volatility: The life sciences industry is highly competitive and subject to rapid technological advancements. Fluidigm Corp needs to continuously adapt to changing market dynamics and customer preferences to maintain its competitive edge.
Opportunities
1. Growing Demand for Single-Cell Analysis: With the increasing interest in personalized medicine and advancements in genomics research, there is a significant opportunity for Fluidigm Corp to capture market share by providing solutions for high-throughput single-cell analysis.
2. Expansion into New Geographical Markets: The company can explore untapped international markets, especially in regions with a rising focus on life sciences research, such as Asia-Pacific. Expanding the customer base beyond traditional markets would help drive revenue growth.
3. Collaboration and Partnerships: Fluidigm Corp can seek strategic collaborations and partnerships with key players in the industry to leverage complementary expertise, access new technologies, and tap into untapped market segments.
Threats
1. Competitive Landscape: The life sciences industry is highly competitive, with several established players and emerging startups continuously introducing new products and technologies. Fluidigm Corp needs to stay vigilant to avoid losing market share.
2. Regulatory and Compliance Challenges: Changes in regulatory requirements and compliance standards can pose challenges for Fluidigm Corp, requiring additional investments and potentially delaying product launches.
3. Economic Uncertainty: Economic downturns or fluctuations can impact research budgets, potentially leading to reduced spending on innovative technologies offered by Fluidigm Corp.
Standard BioTools Employees
3 Years
5 Years
10 Years
25 Years
Max
Details
Standard BioTools Segments
Standard BioTools Revenue by Segment (1/5)
3 Years
Max
Details
Standard BioTools Revenue by Segment (2/5)
3 Years
Max
Details
Standard BioTools Revenue by Segment (3/5)
3 Years
5 Years
10 Years
25 Years
Max
Details
Standard BioTools Revenue by Segment (4/5)
3 Years
5 Years
10 Years
25 Years
Max
Details
Standard BioTools Revenue by Segment (5/5)
3 Years
Max
Details
Standard BioTools Revenue by Region
3 Years
5 Years
Max
Details
Standard BioTools Eulerpool Fair Value
Details
Fair Value Estimate
ⓘWhat Is Fair Value?
Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.
Earnings-Based Fair Value
Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.
Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021
Revenue-Based Fair Value
Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"
Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021
Dividend-Based Fair Value
Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.
Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021
How to Use This Chart
When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.
Standard BioTools historical P/E ratio, EBIT multiple, and P/S ratio
Standard BioTools annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down Standard BioTools's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in Standard BioTools's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare Standard BioTools's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Standard BioTools shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Current Standard BioTools forecasts and price targets in September 2026
Analyst Price Targets 2026Standard BioTools Analyst Rating Actions
| Date | Firm | Action | Rating | Reliability |
|---|---|---|---|---|
| 11/5/2025 | Maintained | Hold | 58 | |
| 2/27/2025 | Downgrade | OverweightSector Weight | 40 | |
| 10/31/2024 | Maintained | Buy | 58 | |
| 8/1/2024 | Maintained | Buy | 58 | |
| 8/26/2020 | Maintained | Buy | 49 | |
| 8/9/2020 | Maintained | Buy | 49 | |
| 11/5/2019 | Downgrade | BuyNeutral | 72 | |
| 10/17/2019 | Upgrade | NeutralBuy | 49 | |
| 1/2/2019 | Upgrade | NeutralBuy | 72 | |
| 11/1/2018 | Upgrade | NeutralOverweight | 54 |
Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.
Standard BioTools Earnings Estimates & Surprises
| Date | EPS estimate | EPS Actual | Revenue Estimate | Price reaction | Quarterly report |
|---|---|---|---|---|---|
| 11/3/2026 | -0.02USD | - | 18.80 MUSD | - | 2026 Q3 |
| 8/5/2026 | -0.01USD | -0.07USD | 20.80 MUSD | - | 2026 Q2 |
| 5/5/2026 | -0.02USD | -0.02USD | 17.80 MUSD | - | 2026 Q1 |
| 2/24/2026 | -0.03USD | 0.06USD | 18.50 MUSD | - | 2025 Q4 |
| 11/4/2025 | -0.04USD | -0.09USD | 18.00 MUSD | - | 2025 Q3 |
| 8/11/2025 | -0.04USD | -0.04USD | 39.82 MUSD | - | 2025 Q2 |
| 5/6/2025 | -0.04USD | -0.04USD | 40.10 MUSD | - | 2025 Q1 |
| 2/26/2025 | -0.07USD | -0.05USD | 43.03 MUSD | - | 2024 Q4 |
| 10/30/2024 | -0.08USD | -0.05USD | 41.00 MUSD | - | 2024 Q3 |
| 7/30/2024 | -0.06USD | -0.08USD | 48.25 MUSD | - | 2024 Q2 |
EESG©
Eulerpool ESG Scorecard© for the Standard BioTools stock
EEnvironment
Environment
SSocial
Social
GGovernance (Corporate Governance)
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Standard BioTools shareholder structure
| % | Name |
|---|---|
20.03767% | |
15.25110% | |
5.66688% | |
4.40200% | |
2.61851% | |
1.93492% |
Standard BioTools Beneficial Ownership Filings (SEC 13D/G)
| Stake | Holder | Filing |
|---|---|---|
23.90% | SEC ↗ | |
22.70% | SEC ↗ | |
18.50% | SEC ↗ | |
18.50% | SEC ↗ | |
15.00% | SEC ↗ | |
15.00% | SEC ↗ | |
15.00% | SEC ↗ | |
15.00% | SEC ↗ | |
11.20% | SEC ↗ | |
11.20% | SEC ↗ |
Standard BioTools Executives and Management Board
9 members · avg. age 59 · 11 % women
Dr. Michael Egholm (62)
President, Chief Executive Officer, Director · since 2022
8.34 M USD
Management
Mr. Sean Mackay (42)
Chief Business Officer
Mr. Hanjoon Kim (54)
Chief Financial Officer
Board of Directors
Mr. Thomas Carey (63)
Independent Chairman of the Board
Dr. Franklin Witney (71)
Independent Director
Mr. Troy Cox (60)
Independent Director
Mr. Fenel Eloi (67)
Independent Director
Ms. Kathy Hibbs (61)
Independent Director
Mr. Eli Casdin (52)
Independent Director
Standard BioTools Supply Chain
Standard BioTools Supply Chain
Correlation: how closely stock prices move together
| # | Name | Trend | |||
|---|---|---|---|---|---|
| 1 | — | — | — | ||
| 2 | — | — | — | ||
| 3 | PerkinElmer | — | — | — | |
| 4 | — | — | — |
Frequently asked questions about Standard BioTools
The business model of Fluidigm Corp focuses on providing innovative technologies for large-scale biological research. The company develops and sells microfluidic systems, instruments, consumables, and software solutions that enable scientists to analyze biological systems at the cellular level. Fluidigm Corp's platforms are designed to enhance workflows and deliver high-quality data for a wide range of applications, including genomics, proteomics, and single-cell analysis. By offering comprehensive and advanced solutions, Fluidigm Corp aims to empower researchers in their quest for new discoveries and deeper understanding of biological processes.
Fluidigm Corp is primarily active in the life sciences industry.
The main competitors of Fluidigm Corp in the market include companies such as Illumina, Thermo Fisher Scientific, and Agilent Technologies.
Fluidigm Corp is a renowned biotechnology company that specializes in the development and commercialization of innovative tools for life sciences research. Founded in 1999, Fluidigm Corp has consistently addressed critical challenges in various fields including genomics, proteomics, and single-cell analysis. The company's cutting-edge microfluidic technologies enable researchers to gain insights into biological systems with higher precision, efficiency, and cost-effectiveness. With a commitment to advancements in medical diagnostics, drug discovery, and personalized medicine, Fluidigm Corp continues to revolutionize the way researchers analyze and understand complex biological processes.
Fluidigm Corp has achieved significant milestones throughout its history. Some key accomplishments include the development and commercialization of innovative microfluidic solutions for life sciences research and clinical diagnostics. The company's revolutionary biomarker detection technology, CyTOF®, has gained widespread recognition for its ability to provide high-resolution single-cell analysis. Additionally, Fluidigm Corp has expanded its product portfolio by introducing high-throughput genotyping and gene expression systems, empowering researchers to unlock valuable insights into complex biological processes. The company's dedication to scientific excellence and ongoing innovation has helped establish Fluidigm Corp as a pioneering force in the field of microfluidics and life sciences.
Fluidigm Corp is primarily present in countries and regions across the globe. With a strong international presence, the company operates in key markets such as North America, Europe, Asia Pacific, and Latin America. Fluidigm Corp's cutting-edge technologies and innovative solutions have gained recognition and adoption worldwide, allowing it to serve customers and partners in various industries and research fields. From its headquarters in South San Francisco, California, Fluidigm Corp has expanded its reach, establishing offices, collaborations, and customer relationships in numerous countries and regions, solidifying its position as a global leader in pioneering microfluidic technologies and scientific advancements.
Fluidigm Corp represents a set of values and corporate philosophy centered around innovation, collaboration, and scientific advancement. With a focus on developing and commercializing transformative technologies, Fluidigm Corp strives to empower researchers and clinicians to make groundbreaking discoveries. The company's dedication to precision and accuracy in their microfluidic systems is evident in their commitment to providing customers with high-quality tools for genomic research, single-cell analysis, and mass cytometry. With a customer-centric approach, Fluidigm Corp aims to drive advancements in the fields of life sciences and healthcare by enabling deeper insights and accelerating discoveries.
Analysts currently set an average price target of 1.58 USD for the Standard BioTools stock (median: 1.58 USD), implying +125.1 % versus the latest price. The consensus is based on 7 analyst ratings.
6 analysts currently rate the Standard BioTools stock: 4 recommend buying, 2 holding and 0 selling. For 2026, analysts expect Standard BioTools to generate revenue of 82.50 M USD and earnings per share of -0.10 USD.
Converted at the current exchange rate, the Standard BioTools share trades at 0.67 EUR (0.77 USD).
The Standard BioTools share (LAB) is listed on 5 stock exchanges, including: NASDAQ (FLDM), SIX (Zürich) (FLB.SW), Frankfurt (FLB.F), München (FLB.MU), Düsseldorf (FLB.DU).
Fluidigm is a biotechnology company that develops innovative technology platforms and products for the analysis of single cells, genomics, and proteomics. The company was founded in 1999 and is headquartered in San Francisco, California. Fluidigm offers products and solutions for the study of single cells and cellular processes. The technology platforms include single-cell genomics, single-cell proteomics, and microfluidic systems. These platforms allow researchers to analyze and investigate individual cells. Fluidigm has a wide range of products that can be grouped into three main categories: gene expression, genotyping, and proteomics. Gene expression products are specifically designed for the analysis of single cells, including the C1 system and Biomark HD technology. The Biomark HD system is Fluidigm's flagship product and is used by researchers worldwide for comprehensive analysis of gene expression profiles. Fluidigm's genotyping product line is primarily used in the pharmaceutical industry and includes assays and chips that enable scientists to study individual genes in the human body. The assays are delivered by the EP1 platform, which performs highly precise genotyping processes and saves resources and time. Fluidigm's proteomics platform allows researchers to analyze proteins and proteome chains in single cells. The company offers a wide range of products, including chips, assays, and kits that detect the identity and concentration of proteins based on mass spectrometry. Fluidigm distributes its products worldwide and serves a broad customer base, including leading pharmaceutical and biotech companies, academic institutions, government agencies, and research laboratories. Fluidigm's business model is based on two core strategies, namely technology innovation and market penetration. The company continuously invests in research and development to remain at the forefront of its technology areas. This has resulted in a broad patent portfolio and a growing customer base. Fluidigm's market penetration strategy focuses on selling products to a variety of customers, including academic institutions, government agencies, and companies. The company has built a distribution infrastructure to sell its products worldwide and provide excellent customer support. In summary, Fluidigm is a biotechnology company that develops and sells innovative technology platforms and products for the analysis of single cells, genomics, and proteomics. The business model is based on technology innovation and market penetration strategy to sell its products worldwide and expand its customer base.
The expected revenue of Standard BioTools is 82.50 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Standard BioTools is -38.46 M USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Standard BioTools is currently -7.71. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Standard BioTools stock.
The price-to-sales ratio (P/S) of Standard BioTools is currently 3.59. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Standard BioTools stock.
The Eulerpool Quality Score for Standard BioTools is 2/10.
The ISIN of Standard BioTools is US34385P1084. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Standard BioTools is A0RADJ. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Standard BioTools is LAB. The ticker symbol is used to trade Standard BioTools shares on the stock exchange.
Standard BioTools paid dividends every year for the past 0 years.
Standard BioTools is assigned to the 'Health' sector.
The dividends of Standard BioTools are distributed in USD.
Standard BioTools stock
Standard BioTools Peer Group
Standard BioTools Ticker
Standard BioTools FIGI
All fundamentals and in-depth analysis of Standard BioTools
Our stock analysis for Standard BioTools stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Standard BioTools. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.